ZA202004827B - Anti-cd73 antibodies and uses thereof - Google Patents
Anti-cd73 antibodies and uses thereofInfo
- Publication number
- ZA202004827B ZA202004827B ZA2020/04827A ZA202004827A ZA202004827B ZA 202004827 B ZA202004827 B ZA 202004827B ZA 2020/04827 A ZA2020/04827 A ZA 2020/04827A ZA 202004827 A ZA202004827 A ZA 202004827A ZA 202004827 B ZA202004827 B ZA 202004827B
- Authority
- ZA
- South Africa
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Fats And Perfumes (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862640955P | 2018-03-09 | 2018-03-09 | |
| US201862721044P | 2018-08-22 | 2018-08-22 | |
| US201862786598P | 2018-12-31 | 2018-12-31 | |
| PCT/US2019/020688 WO2019173291A1 (en) | 2018-03-09 | 2019-03-05 | Anti-cd73 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202004827B true ZA202004827B (en) | 2023-06-28 |
Family
ID=67846304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/04827A ZA202004827B (en) | 2018-03-09 | 2020-08-04 | Anti-cd73 antibodies and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11299550B2 (OSRAM) |
| EP (1) | EP3762030A4 (OSRAM) |
| JP (2) | JP7334177B2 (OSRAM) |
| KR (2) | KR102804816B1 (OSRAM) |
| CN (2) | CN118955714A (OSRAM) |
| AU (1) | AU2019231172B2 (OSRAM) |
| BR (1) | BR112020016049A2 (OSRAM) |
| CA (1) | CA3090008A1 (OSRAM) |
| IL (1) | IL276950B1 (OSRAM) |
| MX (1) | MX2020009366A (OSRAM) |
| SG (1) | SG11202007199XA (OSRAM) |
| WO (1) | WO2019173291A1 (OSRAM) |
| ZA (1) | ZA202004827B (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11786551B2 (en) | 2017-09-26 | 2023-10-17 | The Trustees Of The University Of Pennsylvania | Methods for treating heart disease via redirected T cell immunotherapies |
| CR20230030A (es) | 2018-02-27 | 2023-03-10 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b (divisional 2020-0441) |
| MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
| MX2021000116A (es) | 2018-07-05 | 2021-03-29 | Incyte Corp | Derivados de pirazina fusionados como inhibidores de a2a/a2b. |
| EP3861018A4 (en) | 2018-10-05 | 2022-10-26 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | NEWBORN SCREENING FOR PRIMARY IMMUNODEFICIENCIES, CYSTINOSIS AND WILSON'S DISEASE |
| CN111434688A (zh) * | 2019-01-11 | 2020-07-21 | 上海开拓者生物医药有限公司 | Cd73抗体及其制备方法和应用 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| JP7621344B2 (ja) | 2019-09-23 | 2025-01-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 線維芽細胞活性化タンパク質（ｆａｐ）を標的とすることによる腫瘍組織の破壊の方法 |
| EP4041290A4 (en) | 2019-09-23 | 2024-02-07 | The Trustees of the University of Pennsylvania | MONOCLONAL ANTIBODY AGAINST CANINE FIBROBLAST ACTIVATING PROTEIN WHICH CROSS-REACTS WITH MURINE AND HUMAN FIBROBLAST ACTIVATING PROTEIN (FAP) |
| BR112022009317A2 (pt) * | 2019-11-15 | 2022-08-09 | Genzyme Corp | Anticorpos de cd73 biparatópicos |
| WO2021102376A1 (en) * | 2019-11-20 | 2021-05-27 | Abvision, Inc. | Monoclonal antibodies that target human cd47 protein |
| US20220411497A1 (en) * | 2019-12-17 | 2022-12-29 | Phanes Therapeutics, Inc. | Bispecific Antibodies with Alternatively Matched Interchain Cysteines and Uses Thereof |
| AU2020417804A1 (en) | 2020-01-03 | 2022-07-21 | Incyte Corporation | Anti-CD73 antibodies and uses thereof |
| KR20220137013A (ko) | 2020-01-03 | 2022-10-11 | 인사이트 코포레이션 | Cd73 억제제 및 a2a/a2b 아데노신 수용체 억제제 병용 요법 |
| EP4574971A2 (en) | 2020-03-31 | 2025-06-25 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Proteomic screening for lysosomal storage diseases |
| JP2023522365A (ja) * | 2020-04-22 | 2023-05-30 | アケソ・バイオファーマ・インコーポレイテッド | 抗ｃｄ７３抗体とその利用 |
| CA3176321A1 (en) * | 2020-04-22 | 2021-10-28 | Peng Zhang | Anti-cd73-anti-pd-1 bispecific antibody and use thereof |
| WO2021222746A2 (en) * | 2020-04-30 | 2021-11-04 | Arch Oncology, Inc. | THERAPEUTIC SIRPα ANTIBODIES |
| CA3191745A1 (en) * | 2020-08-17 | 2022-02-24 | Akeso Biopharma, Inc. | Anti-cd73 antibody and use thereof |
| WO2022083723A1 (zh) * | 2020-10-23 | 2022-04-28 | 中山康方生物医药有限公司 | 抗cd73的抗体及其用途 |
| CN117285630A (zh) * | 2020-11-09 | 2023-12-26 | 江苏中新医药有限公司 | 抗cd73单克隆抗体及其在制备肿瘤药物中的应用 |
| WO2022122004A1 (zh) * | 2020-12-11 | 2022-06-16 | 上海华奥泰生物药业股份有限公司 | Cd73的抗原结合蛋白及其应用 |
| EP4271384A1 (en) | 2020-12-29 | 2023-11-08 | Incyte Corporation | Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies |
| CN113061177B (zh) * | 2020-12-31 | 2022-07-01 | 浙江大学 | 一种cd73酶活性相关的抗原表位及针对该表位的特异性抗体的制备方法 |
| EP4299589A4 (en) * | 2021-02-24 | 2025-06-11 | Novoprotein Scientififc Inc. | HUMAN ANTI-CD73 ANTIBODY AND ITS USE |
| GB202105110D0 (en) * | 2021-04-09 | 2021-05-26 | Cancer Research Tech Ltd | Anti-CD73 antibodies |
| CA3229705A1 (en) * | 2021-08-19 | 2023-02-23 | Adicet Therapeutics, Inc. | Methods for detection of membrane bound glypican-3 |
| CN116265486A (zh) * | 2021-12-17 | 2023-06-20 | 三生国健药业（上海）股份有限公司 | 结合人cd73的抗体、其制备方法和用途 |
| US12187806B2 (en) * | 2022-03-04 | 2025-01-07 | Development Center For Biotechnology | Anti-CD73 antibodies and use thereof |
| KR20250004779A (ko) | 2022-04-13 | 2025-01-08 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암을 치료하기 위한 병용 요법 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN116063467B (zh) * | 2022-08-24 | 2025-10-14 | 浙江大学医学院附属第一医院 | 抗h10亚型禽流感病毒血凝素蛋白单克隆抗体1f3及其在检测中的应用 |
| WO2024243189A2 (en) * | 2023-05-22 | 2024-11-28 | Board Of Regents, The University Of Texas System | Antigen binding proteins targeting pd-1 |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| CN117567632B (zh) * | 2023-11-27 | 2025-10-24 | 福州迈新生物技术开发有限公司 | 抗cd73蛋白单克隆抗体及其制备方法和应用 |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008007648A1 (fr) | 2006-07-10 | 2008-01-17 | Institute For Antibodies Co., Ltd. | Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens |
| FR3011240A1 (fr) | 2013-10-01 | 2015-04-03 | Centre Nat Rech Scient | Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques |
| US10654884B2 (en) | 2014-04-25 | 2020-05-19 | Boehringer Ingelheim International Gmbh | Purine derivatives as CD73 inhibitors for the treatment of cancer |
| AU2015329982B2 (en) | 2014-10-10 | 2021-05-20 | Innate Pharma | CD73 blockade |
| PT3218406T (pt) * | 2014-11-10 | 2021-06-17 | Medimmune Ltd | Moléculas de ligação específicas para cd73 e seus usos |
| GB2538120A (en) * | 2014-11-11 | 2016-11-09 | Medimmune Ltd | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof |
| LT3221346T (lt) | 2014-11-21 | 2020-11-10 | Bristol-Myers Squibb Company | Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis |
| KR20230125855A (ko) | 2014-11-21 | 2023-08-29 | 브리스톨-마이어스 스큅 컴퍼니 | Cd73에 대항한 항체 및 그의 용도 |
| EP3259288A1 (en) * | 2015-02-20 | 2017-12-27 | Innate Pharma | Cd73 blockade |
| US11130817B2 (en) | 2015-10-12 | 2021-09-28 | Innate Pharma | CD73 blocking agents |
| CN109154611B (zh) * | 2015-12-09 | 2022-04-08 | 科尔沃斯制药股份有限公司 | 人源化抗cd73抗体 |
| WO2017118613A1 (en) | 2016-01-08 | 2017-07-13 | Syddansk Universitet | Bispecific antibodies targeting human cd73 |
| KR20220033522A (ko) * | 2016-03-04 | 2022-03-16 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd73 항체와의 조합 요법 |
| US10793636B2 (en) * | 2016-07-11 | 2020-10-06 | Corvus Pharmaceuticals, Inc. | Anti-CD73 antibodies |
-
2019
- 2019-03-05 EP EP19764477.6A patent/EP3762030A4/en active Pending
- 2019-03-05 CN CN202411072731.7A patent/CN118955714A/zh active Pending
- 2019-03-05 MX MX2020009366A patent/MX2020009366A/es unknown
- 2019-03-05 WO PCT/US2019/020688 patent/WO2019173291A1/en not_active Ceased
- 2019-03-05 SG SG11202007199XA patent/SG11202007199XA/en unknown
- 2019-03-05 KR KR1020207027633A patent/KR102804816B1/ko active Active
- 2019-03-05 US US15/733,540 patent/US11299550B2/en active Active
- 2019-03-05 KR KR1020257013451A patent/KR20250065424A/ko active Pending
- 2019-03-05 BR BR112020016049-0A patent/BR112020016049A2/pt unknown
- 2019-03-05 AU AU2019231172A patent/AU2019231172B2/en active Active
- 2019-03-05 CN CN201980018305.6A patent/CN111867628B/zh active Active
- 2019-03-05 JP JP2020546997A patent/JP7334177B2/ja active Active
- 2019-03-05 CA CA3090008A patent/CA3090008A1/en active Pending
-
2020
- 2020-08-04 ZA ZA2020/04827A patent/ZA202004827B/en unknown
- 2020-08-26 IL IL276950A patent/IL276950B1/en unknown
-
2023
- 2023-08-14 JP JP2023132024A patent/JP7636483B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020016049A2 (pt) | 2020-12-08 |
| SG11202007199XA (en) | 2020-09-29 |
| MX2020009366A (es) | 2020-10-14 |
| JP2023162257A (ja) | 2023-11-08 |
| IL276950A (en) | 2020-10-29 |
| JP2021516057A (ja) | 2021-07-01 |
| KR20250065424A (ko) | 2025-05-12 |
| CN111867628B (zh) | 2024-08-23 |
| CN118955714A (zh) | 2024-11-15 |
| EP3762030A1 (en) | 2021-01-13 |
| IL276950B1 (en) | 2025-12-01 |
| KR102804816B1 (ko) | 2025-05-09 |
| NZ766968A (en) | 2024-12-20 |
| EP3762030A4 (en) | 2022-01-05 |
| WO2019173291A1 (en) | 2019-09-12 |
| KR20200128542A (ko) | 2020-11-13 |
| AU2019231172B2 (en) | 2023-08-24 |
| AU2019231172A1 (en) | 2020-09-03 |
| JP7334177B2 (ja) | 2023-08-28 |
| JP7636483B2 (ja) | 2025-02-26 |
| CA3090008A1 (en) | 2019-09-12 |
| CN111867628A (zh) | 2020-10-30 |
| US11299550B2 (en) | 2022-04-12 |
| US20200399389A1 (en) | 2020-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276950A (en) | Anti-CD73 antibodies and uses thereof | |
| IL282968A (en) | Anti-NKG2A antibodies and their use | |
| SG11202105885WA (en) | Anti-claudin antibodies and uses thereof | |
| IL274152B (en) | Anti-galectin-9 antibodies and their uses | |
| IL271477A (en) | Anti-cd166 antibodies and their uses | |
| IL268734A (en) | Anti-LAG-3 antibodies and uses thereof | |
| IL275826A (en) | Anti-mct1 antibodies and their uses | |
| IL268700A (en) | Anti-PHF-tau antibodies and uses thereof | |
| ZA202006066B (en) | Anti-hla-g antibodies and use thereof | |
| IL269134A (en) | Antibodies against PAR2 and their use | |
| IL289585A (en) | DLL3-targeted antibodies and uses thereof | |
| SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
| IL281202A (en) | Anti-TNFRSF9 antibodies and uses thereof | |
| ZA202100714B (en) | Anti-npr1 antibodies and uses thereof | |
| IL280321A (en) | Antibodies against CXCR2 and their uses | |
| IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
| IL272476A (en) | Anti-Apelin antibodies and their uses | |
| IL277075A (en) | Anti-PHF-tau antibodies and uses thereof | |
| SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
| SG11202112112UA (en) | Anti-galectin-9 antibodies and uses thereof | |
| IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
| IL277330A (en) | Anti-IL-27 antibodies and uses thereof | |
| SG11202012680TA (en) | Anti-l1cam antibodies and uses thereof | |
| IL276548A (en) | Binding antibodies - BCMA and their uses | |
| GB201712032D0 (en) | Antibodies and uses thereof |